Responsible for promotion of a HER2 Directed Therapy for the treatment of patients with HER2 Positive Metastatic Breast Cancer. The molecule is a Monoclonal Antibody employed in conjunction with conventional Chemotherapy. Geography includes all of New Jersey, Philadelphia, Pennsylvania, and the surrounding areas of Philadelphia.

From 2013 to 2020 responsibility entailed exclusive promotion of the entire HER2 Portfolio of Therapies for Breast Cancer. Scope of promotion encompassed treatments for the entire HER2 Positive Breast Cancer Cycle. Beginning with Early Stage or Pre-Operative treatment and concluding with Metastatic Disease. Therapies included Herceptin, Perjeta, and Kadcyla. From 2001 to 2013 I promoted a host Oncology Therapeutics including Xeloda and Tarceva, as well as Avastin and Erivedge. Geography was focused on Northern New Jersey. Counties in Northern New Jersey included Bergen, Hudson, Passaic, Morris and Essex. During my career with Genentech, a member of the Roche Group, I served in several ancillary capacities. Field Based Trainer, Product Team, and Interim Sales Manager were roles I served through management selection. I attended MAP which is a prerequisite for Sales Management selection.